Research programme: autoimmune therapies - Genten Therapeutics/Intrexon

Drug Profile

Research programme: autoimmune therapies - Genten Therapeutics/Intrexon

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genten Therapeutics
  • Developer Genten Therapeutics; Intrexon Corporation
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Coeliac disease

Most Recent Events

  • 28 Sep 2016 Early research in Coeliac disease in USA (unspecified route)
  • 23 Sep 2016 Intrexon corporation enters into Exclusive Channel Collaborations (ECC) with Genten Therapeutics to develop peptides for Coeliac disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top